Evidence map›Paper›PMID 36757427›Full record

ArticleInternational journal of colorectal disease2023

Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study.

Mingjun Zhang, Qing Huang, Chenchen Shi, Yun Feng, Tianjiao Duan, Tianyu Lin, Yuanmin Zhu, Guisheng Liu, Hongxia Li, Yulan Liu and 1 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of colorectal disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Mingjun Zhang *Department of Gastroenterology, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.
Qing Huang *Department of Gastroenterology, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.
Chenchen Shi *Department of Gastroenterology, Peking University People's Hospital, Beijing, China.
Yun FengDepartment of Gastroenterology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Tianjiao DuanDepartment of Gastroenterology, Shaanxi Provincial People's Hospital, Xi'an, China.
Tianyu LinDepartment of Gastroenterology, Aerospace Center Hospital, Beijing, China.
Yuanmin ZhuDepartment of Gastroenterology, Aerospace Center Hospital, Beijing, China.
Guisheng LiuDepartment of Gastroenterology, Shaanxi Provincial People's Hospital, Xi'an, China.
Hongxia LiDepartment of Gastroenterology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yulan LiuDepartment of Gastroenterology, Peking University People's Hospital, Beijing, China. liuyulan@pkuph.edu.cn.
Bo JiangDepartment of Gastroenterology, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China. drjiang@163.com.
Tsinghua University · CNAerospace Center Hospital · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNPeking University People's Hospital · CNShaanxi Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo evaluate the impact of SARS-CoV-2 vaccine on IBD activity.

methodsAdult IBD patients from five large IBD centers in China were enrolled and followed up for 6 months. Patients were divided into vaccinated and unvaccinated groups according to vaccination status. Demographic and clinical data were collected.

resultsA total of 280 individuals (213 UC and 67 CD patients) were enrolled in the study. The unvaccinated and vaccinated groups of UC patients were comparable for basic characteristics, including age (t = - 0.8, p = 0.425), sex (χ

conclusionsSARS-CoV-2 vaccine has no adverse effect on disease activity in IBD population. IBD patients should be recommended to receive SARS-CoV-2 vaccine in time.

Indexed as

Colitis, UlcerativeCOVID-19Crohn DiseaseInflammatory Bowel DiseasesAdultAnimalsChinaChlorocebus aethiopsCOVID-19 VaccinesHumansSARS-CoV-2Vero CellsCOVID-19 VaccinesCrohn’s diseaseDisease activityInflammatory bowel diseasesSARS-CoV-2 vaccinationUlcerative colitis

Identifiers

PMID36757427
PMCPMC9910246
OpenAlexW4319655510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.